Parkinson's disease is a progressive neurodegenerative disorder affecting movement and non-motor functions, driven by degeneration of dopamine-producing neurons in the brain.
The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
Studies found gut microbiome changes linked to Parkinson’s risk before symptoms and hair mineral differences in diagnosed patients. Both findings need larger follow-up studies.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
A cortical tri-culture model using human iPSC-derived neurons and astrocytes has been validated for neurodegenerative drug discovery and neurotoxicity screening. The model successfully identified compound modes of action in blinded testing, addressing a critical need for physiologically relevant cortical models. Neurodegenerative diseases affect approximately 15% of the global population, with prevalence expected to increase with aging populations.
Genomic technologies including whole-genome sequencing and polygenic risk scores are advancing precision medicine for neurodegenerative diseases like Alzheimer's and Parkinson's. Research reveals complex gene interactions in conditions like PTEN hamartoma tumor syndrome and sex-specific metabolic signatures in Alzheimer's disease. The integration of genomics with molecular neurobiology offers potential for more accurate diagnosis and treatment.
Doctors are implanting lab-grown stem cells into Parkinson's patients' brains in a groundbreaking clinical trial to restore dopamine production. The FDA has granted the Phase 1 REPLACE trial fast-track designation, testing iPSC-derived dopamine-producing cells in 12 patients with moderate to severe Parkinson's. Researchers will monitor participants for up to five years to assess motor function restoration and potential side effects.
Researchers have identified DOPA decarboxylase as a quantitative biomarker in cerebrospinal fluid that improves diagnosis of Parkinson's disease and Lewy body dementia. The protein levels are up to 2.5 times higher in affected patients and can differentiate these conditions from Alzheimer's disease. The discovery provides clinicians with an objective diagnostic tool for conditions that are frequently misdiagnosed due to overlapping symptoms.
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597421 |
Fecal Microbiota Transplantation in Parkinson's Disease. |
NOT_YET_RECRUITING | NA |
| NCT07592767 |
RESvEraTrol in Parkinson's Disease (RESET) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07585565 |
A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations |
NOT_YET_RECRUITING | PHASE2 |
| NCT07570212 |
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders |
RECRUITING | NA |
| NCT07569133 |
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease |
ENROLLING_BY_INVITATION | NA |
| NCT07536022 |
At-home taVNS for Neurorehabilitation in Parkinson's Disease |
NOT_YET_RECRUITING | NA |
| NCT07514858 |
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations |
NOT_YET_RECRUITING | PHASE2 |
| NCT07442747 |
Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS |
NOT_YET_RECRUITING | NA |
| NCT07441915 |
Auditory Sleep Stimulation or Sham in People With Parkinson Disease Mild Cognitive Impairment During Cognitive Training |
RECRUITING | NA |
| NCT07403539 |
Speech Learning and Speech Production in Parkinson's Disease |
RECRUITING | NA |
